Thus, targeting the CD47-SIRPα axis, either through the CD47 or SIRPα blockade, may also promote antigen-presenting cell function, and stimulate T cell-mediated anti-cancer immunity (Figure 1) [56,57]. The gene discussed is SIRPA; the disease is cancer.